Investors/Analysts Meet with management- May 27, 2022 at 3.30 p.m. IST in relation to business performance for Q4 & FY22 and other strategic imperatives.
JB Chemicals & Pharmaceuticals Ltd has informed BSE that meeting of the Board of Director of the Company will be held on May 26, 2022, inter alia, to consider and approve:1. Audited Financial Statements/annual finnacial results for the financial year ended March 31, 2022; and 2. Recommendation of final dividend, if any, for financial year 2021-22.
J.B.CHEMICALS & PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/05/2022 ,inter alia, to consider and approve (i) audited financial statements/annual financial results for the financial year ended on March 31, 2022; and (ii) recommendation of final dividend, if any, for financial year 2021-22.
Certificate under Regulation 40(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 for financial year 2021-22
J.B.CHEMICALS & PHARMACEUTICALS LTD. - 506943 - Statement Of Investor Complaints For The Quarter Ended March 2022
BSE India
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Sandeep PhadnisDesignation :- Company Secretary and Compliance Officer
Update on Assignment of Trademark for Azmarda(r) indicated for heart failure patients with reduced ejection fraction (HfrEF) from Novartis AG, Switzerland for India